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Management of pharmacotherapy in elderly with metabolic diseases is challenging and potentially 
inappropriate medications (PIMs) are risk factors for drug interactions and adverse events. The exposure 
to PIMs in elderly outpatients with metabolic diseases and its relationship with polypharmacy and other 
variables was investigated. PIMs prescribed to 207 elderly patients (aged 60 to 96 years) with metabolic 
diseases who attended a University Hospital of Sao Paulo city, Brazil, from April/2010 to January/2011, 
were evaluated. PIMs were detected using both 2003 Beers and 2008 STOPP criteria. The association 
between PIMs and age, gender and polypharmacy was also examined. 2008 STOPP criteria detected more 
PIMs (44.4 %) than 2003 Beers criteria (16.0%, p<0.001). Beers detected mainly PIMs antihypertensive 
(clonidine, 20.0%; doxazosin, 10.0%) and antidepressant (fluoxetine, 15.0%; amitriptyline, 10.0%) 
PIMs. Medicines used for cardiovascular (aspirin, 53.7%) and endocrine system (glibenclamide, 21.3%) 
were PIMs more frequently detected by 2008 STOPP. Unlike age and gender, polypharmacy increased 
the risk of PIMs by both 2003 Beers (OR: 4.0, CI95%: 1.2-13.8, p<0.031) and 2008 STOPP (OR: 6.8, 
CI95%: 3.0-15.3, p<0.001). Beers and STOPP criteria are important tools to evaluate the exposure to 
PIMs, which is strongly associated with polypharmacy in elderly outpatients with metabolic diseases.
Uniterms: Potentially inappropriate medications/elderly/effects. Elderly/metabolic diseases/study. 
Pharmacotherapy/elderly. Beers criteria. STOPP criteria. Polypharmacy.
INTRODUCTION
The prevalence of metabolic diseases, including 
diabetes, dyslipidemia, and hypertension, is rapidly 
increasing worldwide, especially in the older population. 
Patients with metabolic diseases are treated with anti-
hypertensive, lipid-modifying and anti-diabetic drugs that 
can cause drug-drug interactions and other drug-related 
problems. Therefore, management of pharmacotherapy 
in elderly with metabolic diseases is challenging due to 
the potential drug-related problems, which increases the 
risk for adverse events (Zaman Huri, Chai Ling, 2013). 
Treatment of hypertension with methyldopa and clonidin, 
for example, and stimulators of insulin production, 
such as chlorpropamide and glibenclamide, may cause 
bradycardia, orthostatic hypotension and hypoglycemia, 
increasing the risk of falls in elderly.
Potentially inappropriate medications (PIMs) are 
commonly found in elderly pharmacotherapy that requires 
adjustments to overcome the changes in drugs metabolism 
due to decreased physiological functions, which increase 
the risk of drug toxicity (O´Connor, Gallagher, O’Mahony, 
2012). 
Pharmacotherapy for the elderly has specific 
requirements owing to the presence of comorbidities, drug 
interactions and other factors that lead to an increased risk 
of adverse drug reactions (ADRs). Therefore, the detection 
of PIMs in elderly patients could reduce the risk of ADRs 
and provide a safer and more effective pharmacotherapy 
(Pretorius et al., 2013).
Several tools have been developed to detect PIMs 
to assist clinicians in preventing ADRs in the elderly, 
such as Beers and The Screening Tool of Older Persons 
Prescriptions (STOPP) criteria. Beers criteria have lists 
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of medicines mostly prescribed in North America that are 
deemed inappropriate regardless of patients underlying 
conditions or that are considered inappropriate for some 
comorbidities (Fick et al., 2003). STOPP detects PIMs 
with complementary information based on European 
prescribing patterns, in which the list of medicines 
is organized by physiological systems (Gallagher, 
O’Mahony, 2008). Both criteria and the updates have 
proven to be useful in epidemiological studies that address 
the quality of the medications prescribed for the elderly, 
and provide relevant information to establish treatment 
policies in health services (Fick et al., 2015; O’Mahony 
et al., 2015). 
Prevalence of PIMs according to 2003 Beers 
criteria varied from 13% to 27% in primary care settings, 
nursing homes and hospitalized patients from different 
sample populations (Fick et al., 2003, Ryan et al., 2009, 
Leikola et al., 2011; Pasina et al., 2014). Using STOPP 
criteria PIMs were found in 29-44% of acutely ill 
hospitalized patients, primary care centers and nursing 
homes from different countries (Gallagher, O’Mahony, 
2008; Cahir et al., 2010; Liu et al., 2012; Ubeda et al., 
2012; Bradley et al., 2014). 
In Brazil, PIMs detection in primary care centers, 
hospital outpatients and institutionalized older adults have 
been evaluated mainly by 2003 Beers criteria (Obreli Neto, 
Cuman, 2011; Oliveira et al., 2012; Faustino, Passarelli, 
Jacob-Filho, 2013; Cassoni et al., 2014). STOPP criteria 
have been less used to evaluate PIMs in Brazilian subjects 
probably because it is designed for Europe and it is more 
recent than Beers criteria. 
We have investigated the exposure to PIMs in elderly 
outpatients with metabolic diseases using 2003 Beers and 
2008 STOPP criteria and evaluated the relationship of 
the prevalence of PIMs with polypharmacy and other 
variables.
METHODS
Study design and sample population
A cross-sectional study was conducted to evaluate 
the pharmacotherapy and PIMs in elderly outpatients 
who attended the Metabolic Diseases Care Unit of the 
University Hospital (HU), University of Sao Paulo (USP), 
Sao Paulo, Brazil. The study protocol was approved by the 
Ethics Committee of the HU/USP (Protocol # 571/05).
Elderly patients (60 or more years old), according to 
the Brazilian Institute of Geography and Statistics (http://
www.ibge.gov.br), with metabolic diseases (primary 
arterial hypertension, type 2 diabetes, and dyslipidemia) 
were subsequently selected from April 2010 to January 
2011. Clinical data of the patients were obtained from the 
medical records. Patients with metabolic diseases take 
more than one class of medicines to regulate the metabolic 
status and reduce the risk for cardiovascular diseases, 
therefore they are more prone to have PIMs and drug-drug 
interactions.
The sample size (n=207) was calculated considering 
95% confidence level, 5% confidence interval and the 
16% of PIMs (lower rate described in Brazilian studies). 
Subjects prescribed with homeopathic medicines, 
multivitamins or topic medications were not included in 
this study. 
Pharmacotherapy and PIMs 
Medication prescriptions were obtained from 
the medical records and from the Pharmacy Service. 
Information was recorded considering the number of 
medications, therapeutic classes, dosages, frequencies, 
periods and other data. Polypharmacy was considered 
when the patient was prescribed with five or more 
medicines (Viktil et al., 2007). 
PIMs were analyzed using 2003 Beers and 2008 
STOPP criteria that were used because the study was 
carried out from April 2010 to January 2011, previously 
to the publication of the new versions of these criteria.
The 2003 Beers has a list of 48 drugs or classes of 
drugs that should not be prescribed to elderly patients in 
general (>65 years), and a complementary list covering 20 
clinical conditions and therapies that should be avoided 
by elderly presenting with such conditions (Fick et al., 
2003). Dosage and frequencies of administration that 
should not be exceeded were also listed. The medicines 
were deemed inappropriate either because they have not 
proven effective, or pose unnecessary risks of adverse 
effects, considering the existence of safer alternatives.
The 2008 STOPP tool displays a list of 65 drugs/
therapeutic classes grouped by physiological systems 
(cardiovascular, respiratory, and others) (Gallagher, 
O´Mahony, 2008). These drugs may be inappropriate 
when prescribed alone, contraindicated when used 
concomitantly with other drugs or inadequate in specific 
medical conditions.
Statistical Analysis
Statistical analysis was performed using the 
Sigma Stat software v. 3.5 (SPSS Inc., Chicago IL). 
Categorical variables were compared by chi-square test. 
The relationship of PIMs with polypharmacy and other 
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variables was evaluated by Odds Ratio (OR) with 95% 
Confidence Interval (CI). The level of significance was 
considered p < 0.05. 
RESULTS
Table I presents the PIMs detected in 207 elderly 
outpatients, aged 60 to 96 years old, and with high 
prevalence of women (62.8 %). The detection of PIMs 
was higher using 2008 STOPP (44.4 %) when compared 
to that of 2003 Beers criteria (16.0%, p<0.001). Gender 
and age ranges did not influence the prevalence of PIMs 
independently of the criteria used (p>0.05). 
Patients were grouped in ranges of 10 years each to 
evaluate whether age ranges influence PIMs prevalence, 
but no relationship was found using both criteria. The rate 
of PIMs associated with polypharmacy using 2008 STOPP 
criteria was higher than by 2003 Beers lists (p<0.01).
As shown in Table II, the most commonly prescribed 
2003 Beers-detected PIMs were antihypertensive 
vasodilators (30.0%), such as clonidine and doxazosin, 
and antidepressants (25.0%), such as fluoxetine and 
amitriptyline. Moreover, 65% of these PIMs had high 
degree of severity.
Analysis using 2008 STOPP method showed that 
PIMs were predominantly medicines used for treatment of 
cardiovascular (73.2%) and endocrine disorders (23.2%) 
(Table III). Aspirin without indication and glibenclamide 
for type 2 diabetes (T2D) patients were the most prescribed 
PIMs. Aspirin was considered PIM for patients without 
history of coronary, cerebral or peripheral vascular 
symptoms or occlusive event. Other PIMs were related to 
prescriptions of thiazide diuretics for patients with gout, 
high dose of aspirin (over 150 mg/day) for patients with 
cardiovascular-related conditions, and also amitriptyline, 
calcium channel blockers, theophylline and diclofenac. 
Interestingly only aspirin and amitryptiline were detected 
as PIMs by both criteria.
As shown in Figure 1, age and gender were not 
associated with PIMs in this sample. On the other hand, 
patients who took more than 5 medicines (polypharmacy) 
had increased risk for PIMs detected by 2003 Beers 
(OR=4.0, 95%CI=1.2-13.8, p=0.031). The risk was 
even higher when PIMs were detected by 2008 STOPP 
(OR=6.8, 95%CI=3.0-15.3, p<0.001).
DISCUSSION
The 2008 STOPP method detected twice more 
PIMs than 2003 Beers criteria in the elderly outpatients 
with metabolic diseases, which did not differ from the 
results found in other sample populations. The 2008 
STOPP criteria detected a larger number of PIMs than 
the 2003 Beers criteria in community-dwelling older 
adults and in nursing home residents from Spain (Ubeda 
et al., 2012; Blanco-Reina et al., 2014). In Irish long-term 
TABLE I - Pharmacotherapy of elderly outpatients with metabolic diseases, n=207, Sao Paulo, SP
Variable Beers STOPP p
Age 60-69 (77) years 13.0% (10) 42.9% (33) < 0.01
70-79 (85) years 18.8% (16) 43.5% (37) < 0.01
≥ 80 (45) years 15.5% (7) 48.9% (22) < 0.01
p 0.65 0.92
Gender female (130) 15.4% (20) 42.3% (55) < 0.01
male (77) 16.9% (13) 48.0% (37) < 0.01
p 0.92 0.51
Pharmacotherapy < 4 medicines (53) 5.7% (3) 15.5% (8) 0.20
≥ 5 medicines (154) 19.5% (30) 54.5% (84) < 0.01
p 0.027 <0.01
PIMs total 16.0% (33) 44.4% (92) < 0.01
1 per patient 12.0% (25) 35.7% (74) < 0.01
≥ 2 per patient 3.9% (8) 8.7% (18) 0.52
p <0.01 0.01
Number of patients in parenthesis. Variables were compared by chi-square test. PIMs: potentially inappropriate medications; 
STOPP: Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions.
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care residents 2008 STOPP criteria identified a higher 
percentage of PIMs than the 2003 Beers list (O’Sullivan 
et al., 2013).
A systematic review evaluated 13 studies (12 
observational studies and 1 randomized controlled trial) 
that investigated the prevalence of PIMs in older adults 
(Hill-Taylor et al., 2013). Six studies reported 2008 
STOPP criteria as more sensitive than 2002 Beers criteria 
for PIMs detection. According to the authors, the 2008 
STOPP criteria have been used to evaluate the medication 
TABLE II - PIMs in elderly outpatients with metabolic diseases according to Beers criteria, n=207, Sao Paulo, SP
Medication class Medications Severity rating PIMs (40)
Antidepressant fluoxetine high 15.0% (6)
amitriptyline high 10.0 % (4)
Anxiolytic diazepam high 5.0% (2)
clonazepam high 2.5% (1)
Antiarrhythmic amiodarone high 2.5% (1)
Antihypertensive clonidine low 20.0% (8)
doxazosin low 10.0 % (4)
methyldopa high 5.0% (2)
Antiplatelet aspirin high 5.0% (2)
ticlopidine high 5.0% (2)
Laxatives mineral oil high 2.5% (1)
NSAID ketorolac high 2.5% (1)
Oral iron supplement ferrous sulfate (>325 mg/d) low 5.0% (2)
Skeletal muscle relaxant carisoprodol high 2.5% (1)
cyclobenzaprine high 2.5% (1)
Urinary tract antispasmodic oxybutynin high 5.0% (2)
Number of PIMs in parenthesis. NSAID: non-steroidal anti-inflammatory drug; PIMs: potentially inappropriate medications.
TABLE III - PIMs in elderly outpatients with metabolic diseases according to STOPP criteria, n=207, Sao Paulo, SP
System Medication PIMs (108)
Cardiovascular aspirin without indication 53.7% (58)
aspirin (> 150 mg/d) 5.6% (6)
aspirin + warfarin without anti-H2 or PPI 0.9% (1)
amlodipine in constipated patient 0.9% (1)
thiazide diuretics in patients with gout 6.5% (7)
furosemide for edema without signs of CHF 2.8% (3)
carvedilol in patient with urinary incontinence 0.9% (1)
2 beta-blockers; 2 ACE inhibitors (Duplication of pharmacological class) 1.9% (2)
Endocrine glibenclamide in T2D patients 21.3% (23)
propranolol in patients with hypoglycemic episode 1.9% (2)
Central nervous amitriptyline and calcium channel blocker (1 patient with glaucoma and BPH) 1.8% (2)
Respiratory theophylline as monotherapy for COPD 0.9% (1)
Skeletal muscle diclofenac in patient with CRF and hypertension 0.9% (1)
Number of PIMs in parenthesis. ACE: angiotensin converting enzyme; Anti-H2: antihistamine; BPH: benign prostate hyperplasia; 
CHF: cardiac heart failure; COPD: chronic obstructive pulmonary disease; CRF: chronic renal failure; PPI: proton pump inhibitor; 
PIMs: potentially inappropriate medications; T2D: type 2 diabetes.
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profiles of community-dwelling, acute care and long-term 
care older patients in Europe, Asia and North America. 
The detection of PIMs using 2003 Beers criteria 
in our sample was lower than that found in a Brazilian 
primary care setting using both 2003 and 2012 Beers 
criteria (>48.8%), probably due to different clinical and 
socio-demographic factors (Baldoni et al., 2014).
In this study, PIMs detected by 2003 Beers criteria 
were mainly antihypertensive, such as clonidine and 
doxazosin and antidepressants, such as fluoxetine and 
amitriptyline. Moreover 65% of the 40 Beers-detected 
PIMs had high level of severity. Other works have reported 
that long-acting benzodiazepines are the most frequent 
PIMs prescribed for North American and European 
older adults according to the 2003 Beers list (Stafford, 
Alswayan, Tenni, 2011; Gorzoni, Fabbri, Pires, 2012; 
Pasina et al., 2014).
The antihypertensive clonidine is an inappropriate 
drug for elderly people because it can potentially cause 
orthostatic hypotension and adverse effects in the central 
nervous system (CNS). Clonidine was excluded from the 
2008 STOPP because it is rarely prescribed in Europe. 
Moreover, another study that used the PRISCUS criteria, 
a PIM list primarily to be used in Germany, included 
clonidine as PIM for exposing elderly to adverse effects 
such as bradycardia, hypotension, syncope, and sedation 
(Holt, Schmiedl, Thürmann, 2010). In Brazil, clonidine 
is still prescribed, although it is not indicated as initial 
monotherapy for blood pressure control. Thus, it is worth 
questioning whether clonidine should be excluded from a 
list of prescription drugs for seniors in Brazil.
The antihypertensive doxazosin accounted for 10 % 
of PIMs according to the 2003 Beers in our sample. On the 
other hand it was disregarded as a PIM by 2008 STOPP 
because it is suitable for elderly patients with resistant 
hypertension (Gallagher, O’Mahony, 2008). A limitation 
of our study is that it was not possible to determine 
whether individuals with prescription of doxazosin have 
refractory hypertension to other treatments, since there 
was not such a level of detail in the patients’ records. 
However, doxazosin is indicated to control symptoms of 
urinary obstruction in benign prostatic hyperplasia (Kirby 
et al., 2003), which was observed in one patient to whom 
doxazosin was prescribed.
The antidepressant fluoxetine is considered a PIM 
by the 2003 Beers criteria due to its long half-life and 
increased risk for excessive CNS stimulation, restlessness, 
and sleep disorders (Fick et al., 2003; Laroche et al., 
2007). 
In addition to the aforementioned medicines 
(clonidine, doxazosin and fluoxetine), other PIMs were 
detected only by 2003 Beers, including those that target the 
central nervous (amitriptyline, diazepam and clonazepam) 
and cardiovascular (methyldopa, aspirin, ticlopidine) 
systems. In Brazil, some of these medicines are part of 
the “Farmácia Dose Certa” (Right Dosage Pharmacy), 
a program available in the Sao Paulo State to provide 
some free of charge medicines in the primary care setting 
(Lucchetti et al., 2011). This program has significant 
economic and social benefit, especially for the poorest 
people served by the Brazilian health system. However, 
the prescription must be careful mainly for the elderly 
population in order to avoid PIMs.
In this study, the main PIM detected by 2008 STOPP 
criteria was aspirin without indication, including patients 
without history of coronary, cerebral or peripheral vascular 
symptoms or occlusive event. The requirements of the 
daily dose of aspirin were 100 to 300 mg according to the 
FIGURE 1 - Factors associated with PIMs in elderly outpatients according to Beers and STOPP criteria. 95% confidence interval 
is shown in parenthesis. PPH: polypharmacy (≥ 5 medicines); PIMs: potentially inappropriate medications.
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disease and cardiovascular risk. However according 2008 
STOPP the use of more than 150 mg/day increases the risk 
of bleeding without evidence of effectiveness (Gallagher, 
O’Mahony, 2008).
Other studies have also reported high prevalence 
of prescription of non-steroid anti-inflammatory drugs 
(NSAIDs) detected by 2008 STOPP (Ubeda et al., 2012; 
Blanco-Reina et al., 2014; Vezmar Kovačević et al., 2014). 
Even though the international guidelines continue to 
indicate low-dose aspirin for reducing cardiovascular risk, 
this benefit may not overcome the risk of gastrointestinal 
bleeding in older patients (Lanas, Polo-Tomás, Casado-
Arroyo, 2013; Ikeda et al., 2014). In the recent review 
of the 2015 STOPP criteria, aspirin with concurrent high 
bleeding risk was one of the proposed criteria rejected by 
the expert panel because it could not be considered a PIM 
in every case (O´Mahony et al., 2015).
Glibenclamide was also pointed out by 2008 STOPP 
as a major PIM. It is considered unsuitable for elderly 
T2D patients due to the risk of prolonged hypoglycemia, a 
known ADR of sulfonylureas (Deusenberry et al., 2012). It 
is likely that the increase in prescription of glibenclamide 
is due to its availability by the “Farmácia Dose Certa” 
Program, in Sao Paulo State (Lucchetti et al., 2011).
Importantly, the majority of the PIMs detected by 
the 2003 Beers (87.5%) are not included in the 2008 
STOPP, because each method has a different set of rules. 
Amitriptyline was considered a PIM in a few cases by 
both criteria, while aspirin was a major PIM according 
to 2008 STOPP but a minor PIM by 2003 Beers. It has 
been suggested that the use of both 2012 Beers and 2008 
STOPP may be complementary to detect PIMs in older 
adults (Blanco-Reina et al., 2014). However, a general 
guideline including these lists may not be suitable for all 
populations, considering that the medications approved for 
commercialization may differ between countries.
We did not found association of PIMs with age 
or gender in this sample population. Other studies have 
found a relationship of female and increased risk for PIMs 
(Faustino, Passarelli, Jacob-Filho, 2013; Baldoni et al., 
2014; Cassoni et al., 2014).
Polypharmacy was associated with an increased 
risk of PIMs in elderly outpatients independently of the 
criteria used, even though polypharmacy-related PIMs 
were more prevalent using 2008 STOPP than 2003 Beers 
criteria. Polypharmacy, renal impairment and poor lipid 
control have been shown to be associated with drug-related 
problems in diabetic and dyslipidemic patients (Zaman 
Huri, Chai Ling, 2013), suggesting that elderly patients 
with metabolic diseases may be more exposed to PIMs.
Previous studies have also shown a relationship 
between polypharmacy and PIMs using both 2003 Beers 
and 2008 STOPP in different settings, such as primary 
care programs, community pharmacies, nursing homes, 
and university hospitals (Ryan et al., 2009; Cahir et al., 
2010; Maio et al., 2010; Gallagher et al., 2011; Chen et al., 
2012). Studies conducted in health primary care centers, 
outpatient clinics and long term care settings have also 
reported a strong association between polypharmacy and 
risk of PIMs in Brazil (Oliveira et al., 2012; Faustino, 
Passarelli, Jacob-Filho, 2013; Santos et al., 2013; Vieira 
de Lima et al., 2013; Cassoni et al., 2014).
The results from this study may be limited by the 
size sample and the version of the Beers and STOPP 
criteria used to detect PIMs. The criteria upgrades were 
based on inclusion of new licensed drugs that have been 
proven to be potentially inappropriate or exacerbate 
diseases or risk conditions for the elderly. Other drugs 
were excluded from the former criteria due to lack of 
scientific evidence or withdrawn from the market (Fick et 
al., 2015; O’Mahony et al., 2015). It is possible that the 
use of the revised criteria may reveal higher prevalence of 
PIMs, as it has been reported in recent Brazilian studies 
according to 2012 Beers (35.0-51.8%) (Ganassin, Matos, 
Toffoli-Kadri, 2014; Martins et al., 2015; Oliveira et al., 
2015). 
We also could not evaluate the ADRs related to PIMs 
in this sample population, such as sedation, confusion, and 
lack of balance (long-acting benzodiazepines), or increased 
risk of orthostatic hypotension (clonidine), hyponatremia 
(fluoxetine), and hypoglycemia (glibenclamida). These 
conditions can cause dizziness and consequent fall and hip 
fracture, which increase the risk of thrombosis. Moreover, 
aspirin without indication increases the risk of ulcer and 
bleeding in the elderly (Fick et al., 2003; Gallagher, 
O’Mahony, 2008).
In conclusion, 2008 STOPP is more sensitive than 
2003 Beers criteria to detect PIMs, which are strongly 
associated with polypharmacy in elderly outpatients with 
metabolic diseases. Moreover, updated criteria may be 
used as complementary to evaluate PIMs by healthcare 
practitioners in order to reduce the risk of ADRs in elderly 
patients.
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